File: '\\swfile\EmailIn\20261008 172437 Attachment ASEP PR - 1 million facility.docx'

Asep Medical Holdings Inc.

1

FOR IMMEDIATE RELEASE

Asep Medical Announces $1 million Secured Loan Facility

VANCOUVER, BC, October 8, 2026 - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB:SEPSF) (FSE: JJ8) announces that it has entered into a loan facility agreement dated October 8, 2026 (the "Loan Agreement"), with an arm's length private lender (the "Lender") in respect of a non-revolving term loan facility in the principal amount of US$1 million (the "Facility"). The proceeds of the Facility will be used to fund the Company's short-term working-capital requirements, ordinary-course operating expenses and general corporate purposes.

The Facility will be advanced partially or fully no later than five (5) days following written request and will mature twenty-four (24) months from the execution of the Facility (the "Maturity Date"), subject to earlier acceleration following the occurrence and continuation of an event of default. The Facility will bear interest at a rate of 12% per annum. The Company may voluntarily prepay the Facility and all accrued interest, in whole or in part any time prior to the Maturity Date. The Facility is secured against a general security over all present and after-acquired personal property of the Company, including accounts, equipment, inventory, cash, contractual rights, intellectual property and all proceeds thereof.

No securities of the Company will be issued in connection with the Facility, and no finder's fee, commission or loan bonus is payable.

The advance of funds under the Facility remains subject to the satisfaction or waiver of the conditions precedent contained in the Loan Agreement, and acceptance of the Canadian Securities Exchange, to the extent required. Closing of the Facility is expected to occur on Friday, October 9, 2026.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is an investment issuer focused on investing into biotechnology research and development assets and is based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a significant interest in two private companies - Sepset Biosciences (Asep's leadingproduct, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin, Marketing Director ASEP Medical Holdings Inc.

E. chris@asepmedical.com

T. +1 (604) 362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include, but are not limited to, statements with respect to the expected retention by Asep of a 45% voting interest and 5% preferred share interest into Sepset and ABT; the expectation that no securities of Asep will be issued in connection with the Transaction; the receipt of regulatory approval for the Transaction; the anticipated absence of shareholder approval; the expected strategic relationship among Asep, ABT and Sepset; the parties' ability to collaborate and obtain access to customers, technology, data, networks and commercial opportunities; the strategic direction and business plans of Asep, ABT and Sepset; the finalization and performance of the agreements; the parties will be able to identify and implement commercially viable collaboration opportunities; Asep will maintain access to vendors, infrastructure and customers; Asep will continue to operate independently; and general economic, capital-market, technology and regulatory conditions will not change materially. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management on the date the statements are made and are subject to a variety of risks, including risks associated with the business of the Company and the Company's ability to generate revenue in the future.

This news release contains forward-looking information within the meaning of applicable securities laws, including statements relating to the funding of the Facility, the intended use of proceeds, the execution and delivery of the applicable security documents and the Company's ability to service and repay the Facility.

Forward-looking information is based on management's current expectations, assumptions and estimates and is subject to risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, the risk that the conditions precedent to funding are not satisfied or waived, any required acceptance of the Canadian Securities Exchange is not obtained, the applicable security documents are not completed on the anticipated terms or at all, anticipated receivables are not realized, the Company does not generate sufficient cash flow to service or repay the Facility, and other risks described in the Company's continuous disclosure filings available under its profile on SEDAR+.

Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.